Application of the Hybrid Closed-Loop Artificial Pancreas System in Neurosurgical Perioperative Hyperglycemic Patients: An Open, Randomized Controlled Trial
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Time in Range (TIR)
研究概览
简要总结
In this study, we plan to use an open-source hybrid closed-loop artificial pancreas system and a combination of a traditional insulin pump and continuous glucose monitoring (CGM) respectively to conduct short-term intensive insulin treatment for patients with type 2 diabetes mellitus (T2DM) during the perioperative period who are hospitalized in the Department of Neurosurgery of Shanxi Bethune Hospital. By comparing the blood glucose control status of patients under different intensive insulin treatment regimens and other clinical indicators such as postoperative complications, we will comprehensively evaluate the clinical efficacy and safety of the hybrid closed-loop artificial pancreas system.
详细描述
According to the inclusion and exclusion criteria, 40 perioperative patients with type 2 diabetes mellitus (T2DM) will be screened and enrolled from the neurosurgical ward of Shanxi Bethune Hospital. They will be randomly divided into two groups: 20 patients in the hybrid closed-loop artificial pancreas system group and 20 patients in the traditional pump combined with continuous glucose monitoring (CGM) group. Both groups of patients will use continuous glucose monitoring to measure blood glucose levels. After collecting baseline data, the two groups of patients will receive short-term intensive insulin therapy according to the above-mentioned plans. Relevant clinical data will be collected during and after the treatment to compare the advantages and disadvantages of the two intensive insulin treatment plans in controlling blood glucose levels in perioperative T2DM patients undergoing neurosurgery and their impact on complications.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged between 18 and 75 years old.
- •Patients who have undergone neurosurgical procedures for intracranial hemorrhage (including subdural hemorrhage, basal ganglia hemorrhage, and subarachnoid hemorrhage), have a Glasgow Coma Scale score of 12 or higher after leaving the intensive care unit, receive enteral nutrition postoperatively, and have a previously established diagnosis of type 2 diabetes mellitus, or meet the diagnostic criteria for type 2 diabetes mellitus in the "Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes" (2020 edition) .
- •Fasting blood glucose ≥ 7.0 mmol/L or random blood glucose ≥ 11.1 mmol/L.
- •Those who have signed the informed consent form and are willing to participate in this clinical trial voluntarily.
排除标准
- •Patients with diabetic emergencies, such as diabetic ketoacidosis, hyperglycemic hyperosmolar coma, etc.
- •Patients with type 1 diabetes or other special types of diabetes.
- •Patients with severe cardiac and renal dysfunction: those with cardiac function above grade III; those with serum creatinine exceeding 442 μmol/L.
- •Patients with diseases that affect glucose metabolism, such as hyperthyroidism, hypothyroidism, Cushing's syndrome, etc.
- •Patients who are allergic to the drugs involved in the clinical diagnosis and treatment plan.
- •Populations and contraindications that are not suitable for insulin pump treatment.
- •Patients with allergic constitution and those who are allergic to adhesive tape.
- •Patients with skin diseases such as rashes and prurigo, or those with abnormal coagulation function.
- •Patients with impaired consciousness or mental diseases, who lack self-control and cannot express themselves clearly.
- •Other situations that the researcher deems inappropriate for participating in the clinical trial.
- •Patients who develop severe complications during or after surgery and are judged by the researcher as unfit for enrollment.
研究组 & 干预措施
Traditional insulin pump group
Based on the patient's weight, the total daily insulin requirement is calculated at 0.3~0.6U/(kg*d) and distributed before meals according to the specific conditions of the patient. Continuous glucose monitoring system is used along with daily capillary blood glucose monitoring (fasting, 2 hours after breakfast, lunch, and dinner, totaling 4 times). Insulin doses are adjusted according to the patient's blood glucose level until the target blood glucose level is achieved.
干预措施: Hybrid Closed-Loop Artificial Pancreas System (Device)
Hybrid Closed-Loop Artificial Pancreas System Group
The open-source hybrid closed-loop artificial pancreas system, utilizing ultra-rapid-acting insulin, was employed for perioperative blood glucose management in neurosurgery. Insulin requirements were calculated based on patient weight. The system auto-adjusted basal rates according to blood glucose, while bolus treatments were manually inputted by nurses following physician instructions. Continuous and daily capillary blood glucose monitoring were conducted.
干预措施: Hybrid Closed-Loop Artificial Pancreas System (Device)
结局指标
主要结局
Time in Range (TIR)
时间窗: During the 5- to 7-day period of hospitalization
The percentage of time that blood glucose is within the target range of 6.0-12.0 mmol/L. The calculation formula is: TIR = (Time within the target range / Total time) × 100%
次要结局
- Perioperative Infection Rate and Inflammatory Markers(During the 5- to 7-day period of hospitalization)
- Adverse event（AE）、Serious adverse event（SAE）(During the 5- to 7-day period of hospitalization)
- Perioperative infection rate and inflammatory markers(During the 5- to 7-day period of hospitalization)
- Suture removal time, total hospital stay days, and postoperative hospital stay days(During the 5- to 7-day period of hospitalization)
- Blood glucose target criteria(During the 5- to 7-day period of hospitalization)
- Time Below Range (TBR)、Time Above Range (TAR)(During the 5- to 7-day period of hospitalization)
- Hypoglycemia Incidence Rate(During the 5- to 7-day period of hospitalization)
- Blood glucose fluctuation level (IQR)(During the 5- to 7-day period of hospitalization)